Mylan Bids Nearly $30 Billion For Perrigo In Generic Market Consolidation Move
This article was originally published in The Tan Sheet
Executive Summary
Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.
You may also be interested in...
ANALYSIS: What Would A Teva-Mylan Deal Mean For India?
The situation is still fluid on a possible merger between Teva and Mylan and will likely see a few quick and dramatic turns over the next few weeks. In the event a deal does click, it would have a significant impact on the two firms’ Indian businesses and also Indian generic manufacturers more generally.
In Brief: Vitamix Expands, No “Probiotic” In E.U. Ads, Mylan Misses On Meda, Akorn Hits On VersaPharm
Vitamix triples manufacturing space; using ‘probiotic’ not allowed in E.U.; Meda rejects Mylan bids; Akorn acquires VersaPharm; La. blocks DXM sales to minors; and more news In Brief.
Perrigo’s Irish Move Sets Stage For International Boost, Net Revenue Gain
OTC private label leader Perrigo acquires Irish firm Elan for $8.6 billion in a deal that will bring tax savings from being incorporated in Ireland, provide a stage for European expansion and tap into Elan’s royalty rights. “Simply stated, we're going to be able to further our international platform,” CEO Joseph Papa says.